GAITHERSBURG, Md., July 29 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the company's malaria vaccine program.
"We appreciate the support this grant offers GenVec. This funding supports the advancement of GenVec technology by moving GenVec into the antigen discovery phase of vaccine development," said Dr. Joseph Bruder, head of GenVec's malaria program.
This grant, valued at approximately $600,000 over two years, will be used to identify new immunogenic antigens for malaria vaccine development. Using the funding from this grant, GenVec will be collaborating with the U.S. Naval Medical Research Center (NMRC) to apply its adenovector technology to the development of malaria vaccine candidates.
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.
|SOURCE GenVec, Inc.|
Copyright©2009 PR Newswire.
All rights reserved